Globus sues J&J over spinal implant; Stryker on the lookout for M&A;

@FierceMedDev: Shorter Tryton side branch stent wins CE mark. Article | Follow @FierceMedDev

@MarkHFierce: J&J is leaving the metal hip replacement business behind. Bloomberg broke a good one: Report | Follow @MarkHFierce

 @DamianFierce: Quest buys Humana's toxicology and clinical lab business. News | Follow @DamianFierce

> Globus Medical ($GMED) is suing Johnson & Johnson ($JNJ), claiming its DePuy unit violated its patent for a spinal implant. Report

> Stryker ($SYK) CEO Kevin Lobo said the medical device giant is still on the hunt for more acquisitions to expand its business. Item

> Indian regulators raided a factory manufacturing medical devices without a license. News

> 2012 Fierce 15 winner CardioDx is touting new data affirming its Corus CAD diagnostic's efficacy in a primary care setting. More

> Taiwan's medical device industry is projected to grow 7% this year. Article

> Devon Medical won a CE mark for its wound therapy system. Story

Biotech News

@FierceBiotech: PPD's BioDuro opens Shanghai discovery lab. FierceCRO story | Follow @FierceBiotech

@JohnCFierce: Amgen, Novartis aim to fuel biotech startups in alliance with Atlas Venture. Report | Follow @JohnCFierce

@RyanMFierce: PTC, bluebird join the IPO frenzy in biotech with genetic therapies. Story | Follow @RyanMFierce

> Sanofi balks on jobs promises at R&D site in Toulouse. Report

> Novo Nordisk completes PhIII hemophilia trial with positive results. Item

> AbbVie, Galapagos extend JAK1 pact into Crohn's disease with $50M carrot. News

> Evotec, Harvard partner up to develop new antibacterials. Story

Pharma News

@FiercePharma: Another pharma deal: Sweden's Recipharm mulls IPO or partial sale, Reuters says. UBS advising. News | Follow @FiercePharma

@EricPFierce: EMA committee backs Bayer's Diane-35 birth control drug, even as off-label acne treatment. Article | Follow @EricPFierce

> Sanofi, France remain at odds over fate of 600 R&D jobs. Article

> India sets controversial price caps on 650 drugs. Story

> GSK tries novel approach in emerging markets: price cuts. Report